Loss of p16INK4a expression is frequently observed in lung cancers (Kratzke et al, 1996), and while inactivation may occur by other mechanisms such as point mutations or homozygous deletions, aberrant methylation is the most frequent method. Here, CDKN2A is linked to lung cancer.